Conference Coverage

Anti-TNF agents may slow erosive hand osteoarthritis


 

AT THE EULAR 2016 CONGRESS

References

Pfizer and UCB supported the investigator-initiated studies and provided the study drugs. Dr. Kloppenburg has received lecturing, consultancy, and investigator fees or grants from AbbVie, APPROACH, GlaxoSmithKline, Levicept, Pfizer, Servier, and UCB, all paid to her institution. All other authors declared no conflicts of interests.

rhnews@frontlinemedcom.com

Pages

Recommended Reading

Acetaminophen ineffective against osteoarthritis pain
MDedge Family Medicine
Less symptomatic patients ‘worse off’ after knee surgery
MDedge Family Medicine
Persistent knee pain predicts structural osteoarthritis early
MDedge Family Medicine
Sustained-release steroid provides prolonged OA pain relief
MDedge Family Medicine
Osteoarthritis hip pain follows four distinct paths
MDedge Family Medicine
Blood biomarker panel studies aim to predict knee osteoarthritis, progression
MDedge Family Medicine
Physical therapy underused for knee osteoarthritis
MDedge Family Medicine
Guideline change advocated on using acetaminophen for OA
MDedge Family Medicine
Allogeneic cell therapy fares well in phase III osteoarthritis trial
MDedge Family Medicine
Phone coaching adds limited benefits in knee osteoarthritis
MDedge Family Medicine